{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001767","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.801882+00:00","generated_at":"2026-05-16T10:59:43.535380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance","bullets":["Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.","FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.","Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.","CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.","Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001767","json":"https://secwatch.observer/filing/0001628280-26-001767.json","markdown":"https://secwatch.observer/filing/0001628280-26-001767.md","text":"https://secwatch.observer/filing/0001628280-26-001767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/0001628280-26-001767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/blfs-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:43.535380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}